Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Shana Tova 5781 https://t.co/2i3E8WZN1y #Science #Business
    about 1 day ago
  • When even PhRMA doesn't want to be a Trump campaign prop ... A Deal on Drug Prices Undone by White House Insistence… https://t.co/JjdVxOTVV6
    about 2 days ago
  • A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $… https://t.co/D8kwt0ng5X
    about 2 days ago
  • New post on Science and Enterprise: Mental Health Drug Company Raises $127.5M in IPO https://t.co/39Xea7VQpV #Science #Business
    about 2 days ago
  • A test for SARS-CoV-2 viruses is shown in field tests to return diagnostic results in 90 minutes with accuracy comp… https://t.co/EuQIPTsL57
    about 2 days ago

Please share Science & Enterprise

Gates Foundation Funds, Invests in Tropical Disease Research

River blindness (America.gov)

(America.gov)

Anacor Pharmaceuticals, a biopharmaceutical company in Palo Alto, California, will receive an award of nearly $18 million from the Bill and Melinda Gates Foundation to discover drug candidates for tropical worm diseases and tuberculosis. Anacor says the Gates Foundation will also invest $5 million in the company’s common stock.

Anacor develops small molecule therapies using a technology based on boron — a naturally occurring element found in fruits, vegetables, milk, and coffee — rather than carbon. The company says boron-based compounds have a unique geometry that makes it possible for the compounds to interact with biological targets differently than carbon-based drugs. In addition, says Anacor, boron’s reactions to biological targets can be modulated to optimize the effectiveness of the drugs and minimize adverse effects.

In the agreement with Anacor, the Gates Foundation will pay Anacor $17.7 million to screen drug candidates to treat the filarial worm diseases onchocerciasis or river blindness, and lymphatic filariasis, also known as elephantiasis. Anacor will also screen drug candidates for tuberculosis. The company says it discovered new techniques for synthesizing boron compounds that make it possible to create new compound families.

In addition, Anacor will expand its library of boron-based compounds to screen for more drug candidates to treat neglected diseases. As part of the agreement, Anacor will provide access to this expanded library for researchers from the Gates Foundation, as well as academic, governmental and other not-for-profit organizations.

Onchocerciasis is an insect-borne disease caused by a parasite, and a major cause of blindness in many African countries, as well as Yemen, and parts of Latin America. Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. The condition affects more than 120 million people worldwide, with about 40 million disfigured and incapacitated by the disease. Tuberculosis is an infectious bacterial disease, which in 2011 affected 8.7 million people, causing 1.4 million deaths.

Read more:

*     *     *

Comments are closed.